7.28
-0.09 (-1.22%)
| Previous Close | 7.37 |
| Open | 7.36 |
| Volume | 1,266,044 |
| Avg. Volume (3M) | 2,080,549 |
| Market Cap | 936,899,648 |
| Price / Sales | 1.62 |
| Price / Book | 1.33 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 |
| Profit Margin | -11.54% |
| Operating Margin (TTM) | -16.56% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Total Debt/Equity (MRQ) | 68.08% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | 7.61 M |
| Levered Free Cash Flow (TTM) | -2.21 M |
| Return on Assets (TTM) | -2.75% |
| Return on Equity (TTM) | -8.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | NeoGenomics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 1.19% |
| % Held by Institutions | 98.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Needham, 92.31%) | Buy |
| Median | 11.00 (51.10%) | |
| Low | 8.00 (Morgan Stanley, 9.89%) | Hold |
| Average | 11.00 (51.10%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 6.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 29 Aug 2025 | 14.00 (92.31%) | Buy | 8.78 |
| 29 Jul 2025 | 8.00 (9.89%) | Buy | 5.25 | |
| Piper Sandler | 04 Aug 2025 | 11.00 (51.10%) | Buy | 5.67 |
| Morgan Stanley | 30 Jul 2025 | 8.00 (9.89%) | Hold | 5.10 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera |
| 30 Jul 2025 | Announcement | NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy |
| 29 Jul 2025 | Announcement | NeoGenomics Reports Second Quarter 2025 Results |
| 01 Jul 2025 | Announcement | NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 |
| 30 Jun 2025 | Announcement | NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care |
| 24 Jun 2025 | Announcement | NeoGenomics Appoints Dr. Marjorie Green to Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |